Bone Mineral Density After Cessation of GH Treatment in Young Adults Born SGA: A 5-Year Longitudinal Study

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3508-3516. doi: 10.1210/jc.2017-00269.

Abstract

Context: Short children born small for gestational age (SGA) have below-average bone mineral density (BMD). Growth hormone (GH) treatment improves height and BMD in short SGA children. Longitudinal data on BMD in adults born SGA, after GH cessation (GH-stop), are lacking.

Objective: To determine BMD in young adults born SGA during 5 years after GH-stop.

Methods: In 173 GH-treated adults born SGA (SGA-GH), BMD of total body (BMDTB) and bone mineral apparent density of lumbar spine (BMADLS) were measured longitudinally at adult height (AH) and 6 months, 2 years, and 5 years thereafter. At 5 years after GH-stop (age 21 years), data were compared with 45 untreated short SGA adults (SGA-S), 59 SGA adults with spontaneous catch-up (SGA-CU), and 81 adults born appropriate for gestational age (AGA).

Results: At GH-stop (mean age 16.4 years), estimated mean (standard error) BMDTB standard deviation score (SDS) was -0.40 (0.1) in males and -0.51 (0.1) in females, followed by a trend toward a decrease of BMDTB in males to -0.59 (0.1) at 5 years after GH-stop (P = 0.06), whereas it remained stable in females [-0.57 (0.1); P = 0.33]. At GH-stop, BMADLS SDS was -0.01 (0.1) in males and -0.29 (0.1) in females, followed by a decrease in males and females to -0.38 and -0.55, respectively, at 5 years after GH-stop (P < 0.001). At 5 years after GH-stop, BMDTB and BMADLS in SGA-GH were similar compared with SGA-S, SGA-CU, and AGA.

Conclusion: After GH-stop, there is a gradual decline of BMADLS, but at the age of 21 years, BMDTB and BMADLS are similar as in untreated short SGA adults.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Age Factors
  • Body Height / drug effects
  • Body Weight / drug effects
  • Bone Density / drug effects*
  • Cohort Studies
  • Female
  • Follow-Up Studies
  • Human Growth Hormone / administration & dosage*
  • Humans
  • Infant, Newborn
  • Infant, Small for Gestational Age / growth & development*
  • Longitudinal Studies
  • Male
  • Reference Values
  • Time Factors
  • Treatment Outcome
  • Withholding Treatment
  • Young Adult

Substances

  • Human Growth Hormone

Associated data

  • ISRCTN/ISRCTN65230311
  • ISRCTN/ISRCTN96883876